[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.170.48. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correction
April 10, 2013

Incorrect Number in Figure in: Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial

JAMA. 2013;309(14):1461. doi:10.1001/jama.2013.3309

Incorrect Number in Figure: In the Original Contribution entitled, “Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial,” published in the March 20, 2013, issue of JAMA (2013;309[11]:1125-1135), one of the values in Figure 1 was incorrect. In the box describing the primary efficacy phase (to death or 6 months), the second line should have read “13 Did not complete, vital status unknown, or GCP violation.” The article has been corrected online.

×